About Blue Jet Healthcare Limited

Founded in 1968, Blue Jet Healthcare Limited is a leading specialty pharmaceutical and healthcare ingredient company, operating as an integrated Contract Development and Manufacturing Organisation (CDMO). Over more than 55 years, the company has established a reputation for complex chemistry capabilities, global regulatory alignment, and long-standing partnerships with innovator and multinational generic pharmaceutical companies as well as FMCG brands.

The company’s vision is to be the growth partner of choice in the global pharmaceutical and healthcare arena, guided by values of quality, integrity, leadership, respect, and sustainability. Its mission emphasises customer delight through delivery of high-quality products and services.

Blue Jet Healthcare operates across three specialised verticals:

• Contrast Media Intermediates – supplying key starting and advanced intermediates to three of the world’s largest manufacturers.

• High-intensity Sweeteners – producing saccharin and its salts via a backward-integrated process with zero by-products.

• Pharma Intermediates and APIs – partnering with global innovators and generic players in chronic and complex therapy areas such as cardiovascular, oncology, CNS and NCEs.

The company has four manufacturing facilities in Maharashtra (Shahad, Ambernath, Mahad, and a solvent storage facility at Morivali) and is expanding into Andhra Pradesh with a new 102.48-acre site. Total installed capacity stands at 1,175.60 KL. Its products reach 30+ countries, supported by 500+ employees, over 350 customers, and 50+ commercialised molecules.

Blue Jet Healthcare Limited’s Business Segments

. Segmental highlights include:

• Contrast Media Intermediates: Expanded iodinated portfolio and commercialised a gadolinium-based product. Nearly 70% of revenue in this segment is secured under long-term supply contracts.

• High-intensity Sweeteners: Stable revenue of Rs 1,335 million with a new calcium saccharin variant launched during the year.
  .

• Pharma Intermediates & APIs: The fastest-growing vertical with over 4x year-on-year revenue growth, driven by scale-up of a cardiovascular intermediate and expansion into neurology and oncology molecules.

Blue Jet Healthcare Limited Key Management

• Mr. Akshay Bansarilal Arora – Executive Chairman

• Mr. Shiven Akshay Arora – Managing Director

• Mr. Naresh Suryakant Shah – Executive Director

• Mr. Popat Bhagwan Kedar – Executive Director

Senior management also includes Mr. Ganesh Karuppannan (Chief Financial Officer), Mr. Vimalendu Kumar Singh (Chief Operating Officer), Mr. Chandrashekhar Parenkey (President – R&D), Ms. Payal Gandhi (Chief Business Strategy Officer), and Ms. Sweta Poddar (Company Secretary & Compliance Officer)

Latest Updates on Blue Jet Healthcare Limited

• Capacity Expansion: Commissioned Plant 6 at Ambernath (Unit II), adding 157 KL for pharma intermediates and contrast media.

• Product Commercialisation: Introduced a gadolinium-based contrast media intermediate and scaled up calcium saccharin production.

• Backward Integration: Progress on Mahad (Unit III) facility for in-house contrast media key starting materials.

• R&D Investment: Committed Rs 400 million to establish a new state-of-the-art R&D centre.

• Future Growth: Board approved acquisition of 102.48 acres in Andhra Pradesh, targeting 1,000 KL capacity in the first phase by FY2028.